CUMYL-PICA, or SGT-56, is a synthetic cannabinoid rooted in indole-3-carboxamide. This compound represents the α,α-dimethylbenzyl analogue of SDB-006. Notably, it made a brief appearance in the New Zealand market in 2013 as an ingredient in synthetic cannabis products, which were legal at the time. However, the product containing CUMYL-BICA and CUMYL-PICA faced a setback when it failed to secure interim licensing approval under the Psychoactive Substances regulatory scheme. This was prompted by reports of adverse events experienced by consumers. CUMYL-PICA exerts its action as an agonist for the cannabinoid receptors, with Ki values of 59.21 nM at CB1 and 136.38 nM at CB2, along with EC50 values of 11.98 nM at CB1 and 16.2 nM at CB2.
CUMYL-PICA, or SGT-56, is a synthetic cannabinoid in the indole-3-carboxamide class. It is the α,α-dimethylbenzyl analogue of SDB-006.
How did CUMYL-PICA become known in New Zealand?
CUMYL-PICA gained some notoriety in New Zealand in 2013 when it was included as an ingredient in legal synthetic cannabis products available at that time. However, it faced regulatory hurdles and was denied interim licensing approval due to reports of adverse events among consumers.
What are the effects of CUMYL-PICA on cannabinoid receptors?
CUMYL-PICA acts as an agonist for cannabinoid receptors. It has Ki values of 59.21 nM at CB1 and 136.38 nM at CB2 and EC50 values of 11.98 nM at CB1 and 16.2 nM at CB2.
Is CUMYL-PICA still legal or available for purchase?
The legal status and availability of CUMYL-PICA may vary by region and over time. It’s essential to check with local authorities and regulations to determine its current position in your area.
Are there any risks or side effects associated with CUMYL-PICA?
Like many synthetic cannabinoids, the use of CUMYL-PICA may be associated with various risks and side effects. These can include anxiety, hallucinations, rapid heart rate, and more. It’s crucial to approach these substances cautiously and be aware of potential adverse effects.
Can CUMYL-PICA cause addiction or dependence?
While the addictive potential of synthetic cannabinoids like CUMYL-PICA is not fully understood, they may lead to psychological and physical dependence. Users should be cautious and avoid regular or heavy use.
Is there ongoing research on CUMYL-PICA?
Research on synthetic cannabinoids is ongoing, including compounds like CUMYL-PICA. Scientists continue to investigate their effects, safety, and potential medical applications.
Where can I find more information about CUMYL-PICA?
For the most up-to-date and accurate information on CUMYL-PICA, consult your local health authorities, scientific research, and relevant publications. It’s essential to stay informed about the substance’s legal status and potential health risks.
References
Delving into Cannabinoid Receptors: In November 2020, research explored the stereochemical and conformational requirements at cannabinoid receptors in relation to synthetic cannabinoids like SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA, shedding light on their interactions and effects. Read More
Risk Assessment Score Table: The New Zealand Ministry of Health published a Risk Assessment Score Table on September 27, 2013, offering insights into assessing and managing risks associated with substances, including synthetic cannabinoids. Access Here
Characterizing Abused Synthetic Cannabinoids: In May 2018, a study conducted molecular and behavioral pharmacological characterization of abused synthetic cannabinoids, including MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA. This research provided valuable insights into the properties and potential risks of these substances. Read More
Cannabinoid Compounds: A patent document (WO 2014167530) from April 11, 2013, discussed various cannabinoid compounds, contributing to the understanding of these substances and their potential applications.
